PE-22-28 Molecular Structure & Chemical Properties

PE-22-28 peptide represents a significant advancement in peptide-based neuropsychiatric research, emerging as a shortened and optimized analog of the naturally occurring peptide spadin. Developed through systematic analysis of spadin’s blood degradation products, this seven-amino acid fragment demonstrates markedly superior TREK-1 channel inhibition compared to its parent compound, with an IC50 of 0.12 nM versus 40-60 nM for spadin – representing an approximately 500-fold improvement in potency. Since its characterization in 2017, PE-22-28 has been investigated across multiple preclinical models examining depression, neurogenesis, stroke recovery, and cognitive function. The peptide’s enhanced stability profile – maintaining biological activity for approximately 23 hours compared to spadin’s 7-hour window – positions it as a particularly promising candidate for neurotherapeutic research applications.

Chemical Structure

2D molecular structure (Source: PubChem)

Technical Specifications

The peptide’s compact seven-amino acid structure was specifically designed to retain the critical TREK-1 binding domain while eliminating portions of the parent spadin peptide that contributed to rapid degradation, resulting in dramatically improved pharmacokinetic properties and enhanced therapeutic potential in neuropsychiatric research models.

PE-22-28 Mechanism of Action

PE-22-28 peptide exerts its biological effects primarily through selective antagonism of TREK-1 (TWIK-related potassium channel-1), a two-pore domain potassium channel that plays crucial roles in neuronal excitability, mood regulation, and neuroprotection. Interestingly, research has revealed that PE-22-28 displays dose-dependent biphasic effects on TREK-1: at low concentrations, the channel activity is increased, while at higher doses it is inhibited. This unique property enables distinct therapeutic applications depending on dose selection – neuroprotection at low doses through TREK-1 activation and antidepressant effects at higher doses through TREK-1 inhibition.

Primary Cellular Pathways

TREK-1 Channel Antagonism – Neuronal Excitability Regulation

Research demonstrates that PE-22-28 peptide exhibits exceptional selectivity and potency for TREK-1 channels, with an IC50 of 0.12 nM in HEK293 cells expressing human TREK-1. Key functional consequences include:

• Enhanced neuronal excitability through reduced potassium efflux during depolarization
• Increased firing rate of serotonergic neurons in the dorsal raphe nucleus, mimicking effects seen in TREK-1 knockout animals
• Selective inhibition without significant effects on related channels including TREK-2, TRAAK, TRESK, or TASK-1 at concentrations up to 100 nM
• Allosteric mechanism appearing to specifically antagonize arachidonic acid-mediated TREK-1 activation

TREK-1 channels are prominently expressed in brain regions controlling mood, memory, and learning – including the prefrontal cortex, hippocampus, and amygdala – positioning PE-22-28’s mechanism directly within circuits implicated in depressive disorders.

Rapid Neurogenesis Induction – Hippocampal Plasticity

PE-22-28 peptide demonstrates remarkable capacity to stimulate neurogenesis in the hippocampus after just four days of treatment, substantially faster than conventional antidepressants which typically require weeks. Research findings include:

• Doubling of BrdU-positive cells in the hippocampus within four days (BrdU is incorporated into newly synthesized DNA during cell replication)
• Increased CREB activation (cAMP response element-binding protein), a transcription factor essential for neuronal plasticity and memory formation
• Enhanced BDNF expression (brain-derived neurotrophic factor) in hippocampal tissue, supporting neuronal survival and growth
• Reversal of hippocampal volume loss associated with chronic stress and depression in rodent models

The neurogenic effects appear central to PE-22-28’s antidepressant properties, as increased hippocampal neurogenesis represents a validated biomarker of successful antidepressant treatment.

Synaptogenesis Enhancement – Neural Network Connectivity

Studies reveal that PE-22-28 peptide potently stimulates synapse formation, measured through upregulation of key synaptic markers:

• Doubled expression of PSD-95 (postsynaptic density protein-95), a critical scaffolding protein at excitatory synapses
• Increased synapsin levels, proteins essential for neurotransmitter release and synaptic vesicle dynamics
• Enhanced proportion of mature dendritic spines in cortical neurons, indicating functional synaptic connections
• Synaptic plasticity improvements potentially underlying cognitive and mood benefits observed in behavioral models

These synaptogenic properties distinguish PE-22-28 from many conventional antidepressants and may contribute to its rapid onset of action.

Serotonergic System Modulation – 5-HT Neurotransmission

Electrophysiological studies demonstrate that PE-22-28 peptide enhances serotonergic neurotransmission through TREK-1 inhibition:

• Increased firing rate of dorsal raphe nucleus 5-HT neurons, comparable to effects observed in TREK-1 knockout mice
• Facilitation of serotonin release in projection areas including prefrontal cortex and hippocampus
• Reduction of 5-HT1A autoreceptor-mediated inhibition, as TREK-1 channels are involved in autoreceptor signaling pathways
• Avoidance of direct receptor agonism, potentially contributing to favorable side effect profile compared to SSRIs

The peptide achieves serotonergic enhancement through modulation of ion channel function rather than direct monoamine transporter or receptor interaction.

Neuroprotection and Anti-Apoptotic Signaling

Research indicates PE-22-28 peptide activates cellular survival pathways and provides neuroprotection in injury models:

• Activation of MAPK and PI3K pathways, key intracellular cascades supporting cell survival
• Protection against staurosporine-induced apoptosis in neuronal cell cultures
• Dose-dependent biphasic effects in stroke models: low doses (0.03 mcg/kg) activate TREK-1 for acute neuroprotection, while higher doses (3 mcg/kg) inhibit TREK-1 for antidepressant effects during recovery
• Prevention of delayed neuronal degeneration in substantia nigra following experimental stroke

PE-22-28 Research Applications & Key Findings

Depression Research

Behavioral Depression Models

Extensive investigations in rodent depression models have demonstrated rapid and robust antidepressant-like effects of PE-22-28:

• Forced swimming test: PE-22-28 peptide treatment (3 mcg/kg for 4 days) reduced immobility time by approximately 43% in mice, indicating active coping behavior rather than behavioral despair
• Tail suspension test: Similar reductions in immobility (approximately 28%) observed after 4-day subchronic treatment
• Novelty-suppressed feeding test: Significantly reduced latency to eat food pellets in anxiogenic environments after 4-day treatment (129 seconds versus 226 seconds in controls)
• Corticosterone-induced depression model: Reversed depressive behaviors induced by chronic corticosterone administration

Notably, these behavioral improvements emerged within 4 days, while fluoxetine (Prozac) showed no effect at this early timepoint, demonstrating PE-22-28’s peptide rapid onset of action.

Comparison to Conventional Antidepressants

Research comparing PE-22-28 to established antidepressants reveals important distinctions:

• Onset of action: PE-22-28 effective within 4 days versus 2-3 weeks for SSRIs
• Mechanism: Ion channel modulation versus monoamine transporter inhibition
• Side effect profile: No observed effects on cardiac function, seizure threshold, pain sensitivity, or libido in preclinical studies
• Neurogenic capacity: More rapid induction of hippocampal neurogenesis compared to chronic SSRI treatment

Stroke Recovery and Post-Stroke Depression Research

Ischemic Stroke Neuroprotection

Research published in 2019 by Pietri and colleagues investigated PE-22-28 (referred to as “mini-spadin” in the publication) in a mouse model of focal cerebral ischemia using middle cerebral artery occlusion (MCAO). The biphasic dosing protocol revealed striking neuroprotective effects:

• Acute neuroprotection phase: Low-dose PE-22-28 (0.03 mcg/kg) administered 30 minutes after stroke onset, once daily for 7 days, activated TREK-1 channels to provide protection during the acute injury phase
• Reduced neuronal death and infarct volume in treated animals compared to controls
• Prevention of body weight loss following stroke, a marker of overall recovery
• Protection of dopaminergic neurons in substantia nigra against delayed degeneration

The study demonstrated that low-dose TREK-1 activation provides neuroprotection, while subsequent high-dose treatment (3 mcg/kg) inhibits TREK-1 for antidepressant effects during chronic recovery.

Motor and Cognitive Recovery

Long-term functional outcomes improved significantly with PE-22-28 peptide treatment in stroke models:

• Enhanced motor coordination assessed via rotarod and pole tests months after ischemic injury
• Improved learning and memory demonstrated in Morris water maze testing
• Sustained neurogenesis detected up to 10 weeks post-stroke via BrdU incorporation
• Reversal of stroke-induced cognitive deficits across multiple behavioral domains

Post-Stroke Depression Prevention

Post-stroke depression (PSD) affects approximately 30-50% of stroke survivors and significantly impairs recovery. PE-22-28 demonstrated preventive effects:

• Reduced depressive behaviors in forced swim test following experimental stroke
• Normalized feeding behavior in novelty-suppressed feeding test during stroke recovery
• TREK-1 expression normalization: Stroke-induced upregulation of TREK-1 reversed by higher-dose PE-22-28 treatment
• Enhanced brain plasticity markers (neurogenesis and synaptogenesis) contributing to mood improvements

Neurodegenerative Disease Research

Alzheimer’s Disease Models

Preliminary investigations suggest PE-22-28 may offer benefits in neurodegenerative contexts through multiple mechanisms:

• CREB upregulation: Alzheimer’s research shows CREB downregulation; PE-22-28’s ability to boost CREB presents potential therapeutic relevance
• Neurogenesis stimulation in hippocampus, a region critically affected in early Alzheimer’s pathology
• Synaptic protein enhancement potentially counteracting synapse loss characteristic of neurodegeneration
• Neuroprotective signaling through MAPK and PI3K pathway activation

Research in this application remains preliminary, with no published studies specifically examining PE-22-28 in transgenic Alzheimer’s models.

Cognitive Enhancement and Learning

The peptide’s effects on hippocampal function suggest potential applications in cognitive research:

• Enhanced spatial memory formation through CREB activation and neurogenesis
• Improved learning capacity in behavioral tasks requiring hippocampal integrity
• Increased neuronal plasticity supporting memory consolidation processes
• Protection of cognitive circuits against stress-induced impairments

PE-22-28 Pharmacokinetics & Metabolism

Absorption & Distribution

PE-22-28 exhibits pharmacokinetic properties substantially improved over its parent compound spadin, with research demonstrating:

• Extended duration of action: Biological effects persist for approximately 23 hours following single administration in mouse models, compared to 7 hours for spadin
• Systemic distribution following intraperitoneal injection in rodent studies
• Brain penetration evidenced by central nervous system effects and neurochemical changes in brain tissue
• Multiple administration routes tested: Intraperitoneal (most common in research), intravenous, and potentially intranasal delivery under investigation

The mechanism enabling the peptide’s improved stability likely involves structural modifications that reduce enzymatic degradation while maintaining the critical TREK-1 binding domain.

Metabolism & Elimination

Limited published data characterize the specific metabolic pathways for PE-22-28, but available research indicates:

• Half-life estimates: Approximately 14-23 hours depending on dose and modification (biotinylated analogs show extended half-life)
• Substantially improved stability compared to parent peptide spadin, which is rapidly cleared within 7 hours
• Presumed peptidase degradation as primary metabolic pathway, typical for small peptides
• Minimal accumulation observed in repeated dosing protocols in animal studies

The extended biological activity relative to plasma clearance suggests either tissue retention, formation of active metabolites, or persistent downstream signaling effects following receptor engagement.

Excretion Pathways

Specific excretion data for PE-22-28 remain incompletely characterized in the literature. General peptide pharmacokinetics suggest:

• Renal elimination likely primary route for peptide fragments following proteolytic degradation
• Hepatic metabolism may contribute to initial biotransformation
• No evidence of bioaccumulation in multi-day dosing protocols extending several weeks
• Dose-dependent pharmacokinetics potentially influencing clearance rates at different concentration ranges

The favorable pharmacokinetic profile – particularly the 3-fold extension of activity duration compared to spadin – represents a key advantage for potential therapeutic development and reduces dosing frequency requirements in research protocols.

PE-22-28 Research Protocols & Administration

Dosing in Published Research

Research investigations have employed distinct PE-22-28 dose ranges depending on the desired effect and experimental model:

Depression and Neurogenesis Studies

• Mouse models: 0.3-3 mcg/kg most commonly used for antidepressant effects (intraperitoneal injection)
• Acute treatment: Single doses of 3 mcg/kg effective in forced swim and tail suspension tests
• Subchronic protocol: 3 mcg/kg once daily for 4 consecutive days sufficient to induce neurogenesis and behavioral improvements
• G/A-PE 22-28 analog: 3.2-32 mcg/kg tested with half-life effects of 14-21 hours

Stroke and Neuroprotection Studies

• Low-dose neuroprotection: 0.03 mcg/kg daily for 7 days post-stroke (TREK-1 activation)
• High-dose antidepressant phase: 3 mcg/kg four times per week for several weeks during recovery
• Biphasic protocol: Sequential low-dose followed by high-dose treatment optimizes outcomes

Important: These are experimental doses used in animal studies and cannot be extrapolated to other species due to significant interspecies differences in metabolism, TREK-1 channel expression patterns, peptide pharmacokinetics, blood-brain barrier permeability, and enzymatic degradation rates. Dose translation from rodents to other species requires species-specific pharmacokinetic and pharmacodynamic characterization.

Administration Routes in Research

Multiple delivery methods have been investigated in preclinical studies:

• Intraperitoneal injection – Most common route in published rodent studies; reliable systemic delivery with consistent bioavailability
• Intravenous injection – Used in some behavioral studies; enables rapid onset but requires more technical administration
• Intranasal delivery – Under investigation as a potential non-invasive route for enhanced brain targeting
• Intracerebroventricular injection – Occasionally used in mechanistic studies requiring direct CNS delivery
• Subcutaneous injection – Feasible alternative route with potentially modified absorption kinetics

Common Model Organisms

PE-22-28 has been studied across several experimental systems:

• Mice – Primary research model (C57BL/6 and Swiss strains most common); vast majority of behavioral, neurogenesis, and stroke recovery data
• Mouse cell culture – Cortical neurons, hippocampal neurons, and dorsal raphe nucleus cells used for mechanistic studies
• HEK293 cells – Expressing human TREK-1 channels for electrophysiological characterization and IC50 determination
• CA3 pyramidal neurons – Acute hippocampal slices from mice used to study native TREK-1 currents
• TREK-1 knockout mice – Genetic deletion models used to confirm mechanism specificity

Notably, larger animal models (rats, rabbits, dogs) have not been extensively utilized in PE-22-28 research to date, with the overwhelming majority of data deriving from mouse studies.

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite promising preclinical findings spanning depression, stroke recovery, and neuroprotection, PE-22-28 faces substantial translational barriers that significantly limit its current research utility and preclude any clinical applications.

Lack of Human Clinical Data

The most significant limitation is the complete absence of human research:

• No published human clinical trials exist in peer-reviewed literature or clinical trial registries
• No Phase I safety studies establishing human tolerability, pharmacokinetics, or appropriate dose ranges
• No Phase II efficacy data in any indication including depression, stroke recovery, or cognitive enhancement
• Human safety profile completely undefined: Tolerability, adverse effects, drug interactions, and contraindications remain unknown
• Optimal human dosing entirely speculative: No established therapeutic window or dose-response relationship in humans

Translation from mouse studies to human applications faces substantial challenges, particularly for CNS-active peptides.

Mechanistic Understanding Gaps

Fundamental aspects of PE-22-28’s mechanism of action require further clarification:

• Biphasic dose-response relationship: The transition point between TREK-1 activation (low dose) and inhibition (high dose) incompletely characterized across different tissues and species
• Downstream signaling specificity: Whether all observed effects are strictly TREK-1-mediated or involve additional targets remains unclear
• Brain regional heterogeneity: TREK-1 expression varies substantially across brain regions; tissue-specific effects require better definition
• Active metabolites versus parent peptide: Contribution of degradation products to biological activity unknown
• Blood-brain barrier penetration mechanisms: How efficiently the peptide crosses into CNS and whether modifications enhance permeability needs characterization

Long-Term Safety Considerations

Critical safety questions remain unanswered even in animal models:

• Chronic administration effects: Most studies limited to several weeks; long-term consequences of continuous treatment undefined
• Neuroplasticity risks: Sustained neurogenesis and synaptogenesis enhancement could theoretically produce unintended circuit modifications
• Cancer risk: Proliferative effects on neural progenitor cells raise theoretical concerns about tumor promotion requiring investigation
• Reproductive and developmental toxicity: Effects on fertility, pregnancy, and fetal development completely unstudied
• Cardiovascular effects: While acute cardiac safety appears favorable in mice, long-term cardiovascular impacts unknown

Regulatory & Competitive Sport Status

FDA Position

PE-22-28 has not received regulatory approval from any health authority worldwide:

• Not approved for any indication by the US Food and Drug Administration
• Classified as an unapproved drug substance without established medical use
• Not recognized as GRAS (Generally Recognized as Safe) for any application
• Not legally available for medical compounding or human therapeutic use
• No orphan drug designation or fast-track status for any condition

The FDA does not currently recognize any legitimate medical use for PE-22-28 outside of controlled research settings.

Competitive Sport Considerations

While no specific regulatory statements regarding PE-22-28 appear in publicly available WADA documentation, peptides with neuropsychiatric or performance-enhancing properties generally face scrutiny:

• Peptides without regulatory approval typically fall under prohibited substances categories in competitive sport
• TREK-1 modulators’ effects on pain perception and stress response could theoretically provide competitive advantages
• Neurogenesis and cognitive effects might enhance training adaptation or decision-making capacity
• Athletes should assume peptides lacking regulatory approval are prohibited in competition pending specific guidance

Research Classification: PE-22-28 is available exclusively for laboratory research use under appropriate institutional oversight. It is not intended for human consumption, medical treatment, veterinary applications, or any use outside of controlled scientific investigation. All research must be conducted under proper ethical review and regulatory compliance with institutional approval.

References

1. Djillani, A., Pietri, M., Moreno, S., Heurteaux, C., Mazella, J., & Borsotto, M. (2017). Shortened spadin analogs display better TREK-1 inhibition, in vivo stability and antidepressant activity. Frontiers in Pharmacology, 8, 643. PubMed
   
2. Pietri, M., Djillani, A., Mazella, J., Borsotto, M., & Heurteaux, C. (2019). First evidence of protective effects on stroke recovery and post-stroke depression induced by sortilin-derived peptides. Neuropharmacology, 158, 107715. PubMed
   
3. Mazella, J., Pétrault, O., Lucas, G., Deval, E., Béraud-Dufour, S., Gandin, C., El-Yacoubi, M., Widmann, C., Guyon, A., Chevet, E., Taouji, S., Conductier, G., Corinus, A., Coppola, T., Gobbi, G., Nahon, J.L., Heurteaux, C., & Borsotto, M. (2010). Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: A new concept in the antidepressant drug design. PLoS Biology, 8(4), e1000355. PubMed
   
4. Heurteaux, C., Lucas, G., Guy, N., El Yacoubi, M., Thümmler, S., Peng, X.D., Noble, F., Blondeau, N., Widmann, C., Dehay, M., Gobbi, G., Vaugeois, J.M., Debonnel, G., & Lazdunski, M. (2006). Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. Nature Neuroscience, 9(9), 1134-1141. PubMed
   
5. Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., Belzung, C., & Hen, R. (2003). Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science, 301(5634), 805-809. PubMed
   
6. Moha ou Maati, H., Veyssiere, J., Labbal, F., Coppola, T., Gandin, C., Widmann, C., Mazella, J., Heurteaux, C., & Borsotto, M. (2012). Spadin as a new antidepressant: Absence of TREK-1-related side effects. Neuropharmacology, 62(1), 278-288. PubMed
   
7. Devader, C., Moreno, S., Roulot, M., Deval, E., Dix, T., Morales, C.R., & Mazella, J. (2015). Increased brain neurotensin and NTSR2 lead to weak nociception in NTSR3/Sortilin knockout mice. Frontiers in Neuroscience, 9, 239. PubMed
   
8. Borsotto, M., Veyssiere, J., Moha ou Maati, H., Devader, C., Mazella, J., & Heurteaux, C. (2015). Targeting two-pore domain K+ channels TREK-1 and TASK-3 for the treatment of depression: A new therapeutic concept. British Journal of Pharmacology, 172(3), 771-784. PubMed
   
9. Duman, R.S., Malberg, J., & Nakagawa, S. (2001). Regulation of adult neurogenesis by psychotropic drugs and stress. Journal of Pharmacology and Experimental Therapeutics, 299(2), 401-407. PubMed
   
10. Krishnan, V., & Nestler, E.J. (2008). The molecular neurobiology of depression. Nature, 455(7215), 894-902. PubMed
    
11. Nestler, E.J., Barrot, M., DiLeone, R.J., Eisch, A.J., Gold, S.J., & Monteggia, L.M. (2002). Neurobiology of depression. Neuron, 34(1), 13-25. PubMed
    
12. Malberg, J.E., Eisch, A.J., Nestler, E.J., & Duman, R.S. (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. Journal of Neuroscience, 20(24), 9104-9110. PubMed
    

*All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. PE-22-28 is intende